Brief: Anthera Pharmaceuticals completes interim analysis from phase 3 trial with blisibimod
16/03/2015 12:44
March 16 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O : * Announces completion of interim analysis from phase 3 trial with blisibimod for iga nephropathy * Says primary efficacy analysis data expected in second half of 2016 * Source text for Eikon ID:nPn7yFSRc * Further company coverage ANTH.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman